Novo Nordisk A/S (NVO) to Release Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) will likely be posting its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.90 per share and revenue of $11.9651 billion for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, analysts expect Novo Nordisk A/S to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $62.90 on Wednesday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The firm has a market capitalization of $280.86 billion, a P/E ratio of 18.29 and a beta of 0.66. The firm’s 50 day moving average is $52.75 and its two-hundred day moving average is $54.50.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Sunbelt Securities Inc. raised its holdings in shares of Novo Nordisk A/S by 58.7% during the 3rd quarter. Sunbelt Securities Inc. now owns 20,993 shares of the company’s stock valued at $1,165,000 after buying an additional 7,764 shares during the period. Advisory Services Network LLC raised its stake in Novo Nordisk A/S by 12.1% during the 3rd quarter. Advisory Services Network LLC now owns 98,850 shares of the company’s stock valued at $5,485,000 after purchasing an additional 10,642 shares during the last quarter. Peloton Wealth Strategists increased its holdings in shares of Novo Nordisk A/S by 39.5% during the third quarter. Peloton Wealth Strategists now owns 36,880 shares of the company’s stock worth $2,046,000 after buying an additional 10,450 shares in the last quarter. Saratoga Research & Investment Management raised its holdings in Novo Nordisk A/S by 22.5% in the third quarter. Saratoga Research & Investment Management now owns 1,853,707 shares of the company’s stock worth $102,862,000 after purchasing an additional 341,030 shares during the period. Finally, Abel Hall LLC boosted its holdings in shares of Novo Nordisk A/S by 27.8% in the 3rd quarter. Abel Hall LLC now owns 7,929 shares of the company’s stock valued at $440,000 after buying an additional 1,724 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent analyst reports. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Jefferies Financial Group began coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating on the stock. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $57.79.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.